Neurocrine Biosciences
NBIX
NBIX
403 hedge funds and large institutions have $7.57B invested in Neurocrine Biosciences in 2021 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 141 increasing their positions, 140 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
1.37% less ownership
Funds ownership: 95.34% → 93.97% (-1.4%)
13% less capital invested
Capital invested by funds: $8.65B → $7.57B (-$1.08B)
14% less call options, than puts
Call options by funds: $44.6M | Put options by funds: $52M
Holders
403
Holding in Top 10
5
Calls
$44.6M
Puts
$52M
Top Buyers
| 1 | +$107M | |
| 2 | +$43.3M | |
| 3 | +$37.2M | |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$35.7M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$35M |
Top Sellers
| 1 | -$238M | |
| 2 | -$131M | |
| 3 | -$79.9M | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$54M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$42.8M |